Literature DB >> 25748360

Novel insights into Chk1 regulation by phosphorylation.

Hidemasa Goto1, Kousuke Kasahara, Masaki Inagaki.   

Abstract

Checkpoint kinase 1 (Chk1) is a conserved protein kinase central to the cell-cycle checkpoint during DNA damage response (DDR). Until recently, ATR, a protein kinase activated in response to DNA damage or stalled replication, has been considered as the sole regulator of Chk1. Recent progress, however, has led to the identification of additional protein kinases involved in Chk1 phosphorylation, affecting the subcellular localization and binding partners of Chk1. In fact, spatio-temporal regulation of Chk1 is of critical importance not only in the DDR but also in normal cell-cycle progression. In due course, many potent inhibitors targeted to Chk1 have been developed as anticancer agents and some of these inhibitors are currently in clinical trials. In this review, we summarize the current knowledge of Chk1 regulation by phosphorylation.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25748360     DOI: 10.1247/csf.14017

Source DB:  PubMed          Journal:  Cell Struct Funct        ISSN: 0386-7196            Impact factor:   2.212


  15 in total

1.  Analysis of Protein Phosphorylation and Its Functional Impact on Protein-Protein Interactions via Text Mining of the Scientific Literature.

Authors:  Qinghua Wang; Karen E Ross; Hongzhan Huang; Jia Ren; Gang Li; K Vijay-Shanker; Cathy H Wu; Cecilia N Arighi
Journal:  Methods Mol Biol       Date:  2017

2.  LAMMER kinase contributes to genome stability in Ustilago maydis.

Authors:  Carmen de Sena-Tomás; Jeanette H Sutherland; Mira Milisavljevic; Dragana B Nikolic; José Pérez-Martín; Milorad Kojic; William K Holloman
Journal:  DNA Repair (Amst)       Date:  2015-06-19

3.  Pyruvate Kinase M1 Suppresses Development and Progression of Prostate Adenocarcinoma.

Authors:  Daniel R Schmidt; Julia E Heyman; James P O'Brien; Amy C Liu; Shawn M Davidson; William J Israelsen; Talya L Dayton; Raghav Sehgal; Roderick T Bronson; Elizaveta Freinkman; Howard H Mak; Giuseppe Nicolò Fanelli; Scott Malstrom; Gary Bellinger; Arkaitz Carracedo; Pier Paolo Pandolfi; Kevin D Courtney; Abhishek Jha; Ronald A DePinho; James W Horner; Craig J Thomas; Lewis C Cantley; Massimo Loda; Matthew G Vander Heiden
Journal:  Cancer Res       Date:  2022-07-05       Impact factor: 13.312

4.  Significant expression of CHK1 and p53 in bladder urothelial carcinoma as potential therapeutic targets and prognosis.

Authors:  Linfeng Zheng; Yuping Zhu; Lei Lei; Wenyong Sun; Guoping Cheng; Shifeng Yang
Journal:  Oncol Lett       Date:  2017-11-03       Impact factor: 2.967

5.  A lethal synergy induced by phellinus linteus and camptothecin11 in colon cancer cells.

Authors:  Tianqi Yu; Suthakar Ganapathy; Ling Shen; Bo Peng; Sung-Hoon Kim; Alexandros Makriyannis; Changyan Chen
Journal:  Oncotarget       Date:  2018-01-04

6.  Melanoma LAMP-2C Modulates Tumor Growth and Autophagy.

Authors:  Liliana Pérez; Anthony L Sinn; George E Sandusky; Karen E Pollok; Janice S Blum
Journal:  Front Cell Dev Biol       Date:  2018-08-29

Review 7.  DNA Damage Signalling and Repair Inhibitors: The Long-Sought-After Achilles' Heel of Cancer.

Authors:  Denis Velic; Anthony M Couturier; Maria Tedim Ferreira; Amélie Rodrigue; Guy G Poirier; Fabrice Fleury; Jean-Yves Masson
Journal:  Biomolecules       Date:  2015-11-20

8.  Potential effect of smoking on semen quality through DNA damage and the downregulation of Chk1 in sperm.

Authors:  Xiangrong Cui; Xuan Jing; Xueqing Wu; Zhenqiang Wang; Qiang Li
Journal:  Mol Med Rep       Date:  2016-05-20       Impact factor: 2.952

9.  CHK1 and RAD51 activation after DNA damage is regulated via urokinase receptor/TLR4 signaling.

Authors:  Pavan B Narayanaswamy; Sergey Tkachuk; Hermann Haller; Inna Dumler; Yulia Kiyan
Journal:  Cell Death Dis       Date:  2016-09-29       Impact factor: 8.469

10.  Chk1 inhibition as a novel therapeutic strategy in melanoma.

Authors:  Bor-Jang Hwang; Gautam Adhikary; Richard L Eckert; A-Lien Lu
Journal:  Oncotarget       Date:  2018-07-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.